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Abstract
Background: Diabetes mellitus is a complicated disease with a pathophysiology that includes hyperinsulinemia,
hyperglycemia and other metabolic impairments leading to many clinical complications. It is necessary to develop
appropriate treatments to manage the disease and reduce possible acute and chronic side effects. The advent of
gene therapy has generated excitement in the medical world for the possible application of gene therapy in the
treatment of diabetes. The glucagon-like peptide-1 (GLP-1) promoter, which is recognised by gut L-cells, is an
appealing candidate for gene therapy purposes. The specific properties of L-cells suggest that L-cells and the GLP-1
promoter would be useful for diabetes therapy approaches.
Results: In this study, L-cells were isolated from a primary intestinal cell line to create suitable target cells for
insulin expression studies. The isolated cells displayed L-cell properties and were therefore used as an L-cell
surrogate. Next, the isolated L-cells were transfected with the recombinant plasmid consisting of an insulin gene
located downstream of the GLP-1 promoter. The secretion tests revealed that an increase in glucose concentration
from 5 mM to 25 mM induced insulin gene expression in the L-cells by 2.7-fold. Furthermore, L-cells quickly
responded to the glucose stimulation; the amount of insulin protein increased 2-fold in the first 30 minutes and
then reached a plateau after 90 minutes.
Conclusion: Our data showed that L-cells efficiently produced the mature insulin protein. In addition, the insulin
protein secretion was positively regulated with glucose induction. In conclusion, GLP-1 promoter and L-cell could
be potential candidates for diabetes gene therapy agents.
Background
Diabetes mellitus is characterised by metabolic disorders
and abnormally high blood glucose, which are caused by
the destruction of the b-cells of the pancreas, insulin
resistance and/or insulin deficiency. Achieving a normal
circulating glucose level is a major goal for therapeutic
intervention in diabetes patients. However, the current
standard of care, which consists of constant monitoring
and precise insulin loading through injections, puts
patients at risk for acute diabetes complications [1].
Gene therapy can be a successful treatment for diabetes
if insulin can be produced through a glucose-regulated
pathway and if the insulin thus produced can elicit
responses to glucose fluctuation levels that are similar
to those induced by natural insulin secretion. Further-
more, candidate cells for gene therapy need to express
enzymes for post-translational processing of pro-insulin
into mature insulin. Some research groups have geneti-
cally modified several cell types to produce functional
insulin [2,3]. However, their studies showed that the
engineered cells could not produce satisfactory insulin
substitutes. This is because the cell types used do not
possess all the essential properties that would mimic the
natural physiological regulation of insulin secretion.
Enteroendocrine cells, which are located in the gut
lumen, secrete incretin horm o n e ss u c ha sg l u c a g o n - l i k e
peptide-1 (GLP-1, from L-cells) and glucose-dependent
insulinotropic polypeptide (GIP, from K-cells) that act on
pancreatic b-cells to stimulate the release of insulin. The
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any medium, provided the original work is properly cited.specific factors that regulate GLP-1 and GIP secretion are
very similar to those that regulate insulin secretion by b-
cells [4]. In addition, L- and K-cells express carboxypepti-
dase H and pro-hormone convertases 2 and 3, the same
processing enzymes used by b-cells to process mature
insulin [5]. Certain properties of enteroendocrine cells,
including glucose sensitivity, insulin processing capability
and a regulated secretion pathway, make them ideal
potential candidate cells for diabetes gene therapy.
Previous studies reported that genetically engineered
K-cells expressed insulin protein under the control of
the GIP promoter [6,7]. Additionally, other studies
showed that a transgenic mouse expressing a recombi-
nant insulin gene under the control of the GIP promo-
ter was capable of normalising blood glucose levels in
response to an increase in glucose consumption [6].
Furthermore, recent studies have revealed that engi-
neered L-cells produced insulin protein as a result of
v a r i o u ss t i m u l i .T h e s er e s u l t sp r o v et h a tL - c e l l sc o n t a i n
the required factors to synthesise, process and secrete
mature insulin [8]. However in these experiments, uni-
versal promoters (such as viral promoters) were
employed to introduce the insulin gene into the L-cells
[9]. Thus, caution has to be exercised because viral pro-
moters are not cell specific and the genes they carry
could therefore be expressed in all types of cells.
GLP-1 is one of the products of the proglucagon gene,
which expresses a number of different hormones in differ-
ent tissues. When glucagon is produced in the a-cells of
the pancreas; glicentin, GLP-I and II are expressed in the
L-cells of the intestine [10]. Extensive research has led to
the identification of a promoter region that mediates cell-
specific gene transcription in each tissue. It was reported
that approximately 2.3 kb of the proglucagon gene 5’-
flanking sequences control highly tissue-specific gene tran-
scription of GLP-1 in the L-cells [11]. The unique proper-
ties of L-cells and the GLP-1 promoter provide a strong
rationale to use the GLP-1 promoter to express glucose-
regulated insulin in intestinal L-cells for the potential
treatment of diabetes. In this study, the region of the pro-
glucagon promoter that is recognised by L-cells was uti-
lised in expressing the insulin gene in vitro. We studied
the ability of the engineered L-cells to produce insulin
under different glucose concentrations and at various time
points. For these purposes, we extracted L-cells from
intestinal endocrine cells [12]. The extracted cells are use-
ful for the cell-based study of intestinal L-cells, specifically
in the investigations of its potential as a gene-therapy can-
didate for diabetes treatment.
Methods
Plasmid construction
To construct the plasmid, the proglucagon promoter
region (approximately 2,300 bp) was amplified from the
Glu.BS plasmid, which was kindly provided by Dr. Yvan
Gosmain from the University of Geneva [13]. In addi-
tion, a human insulin gene (approximately 1,800 bp)
was obtained from human genomic DNA. Furthermore,
approximately 1,200 bp of a neomycin resistant gene
was amplified from pcDNA3 plasmid (Invitrogen, USA).
To produce GLP-1/Ins/pBud plasmid, the proglucagon
promoter fragment and insulin gene were inserted into
the pBudCE4.1 vector (Invitrogen, USA). Similarly, the
proglucagon promoter and neomycin resistant gene
were cloned into a pBluescript-II-SK vector (Stratagene,
USA) to create a GLP-1/Neo/pBlu plasmid (Figure 1).
Figure 1 Construction and restriction maps of recombinant plasmids. (A) Schematic diagram of GLP-1/Ins/pBud plasmid: GLP-1 promoter
(GLP-1 pro, blue part) and insulin gene (red part) in the pBudCE4.1 vector. The pBudCE4.1 vector contains the zeocin resistant gene. (B)
Schematic diagram of GLP-1/Neo/pBlu plasmid: GLP-1 promoter (GLP-1 pro, blue part) and neomycin resistant gene (Neo) in the pBluescript-II-SK
vector. The pBluescript-II-SK vector contains the ampicillin (Amp) resistant gene.
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restriction enzymes used are illustrated in table 1. All
the enzymes and kits were purchased from Fermentas,
Lithuania.
Cells and transfection
The STC-1 cell line that was derived from an endocrine
tumour of the murine intestine was kindly provided by
Prof. Douglas Hanahan from the University of Califor-
nia. The STC-1 cells were cultured in DMEM (Dulbec-
co’s Modified Eagle’s Medium; PAA, Austria) containing
10% FBS (Fetal bovine serum; PAA, Austria). Cells were
transfected with the GLP-1/Ins/pBud plasmid or GLP-1/
Neo/pBlu plasmid using Lipofectamine 2000 Transfec-
tion Reagent (Invitrogen, USA). After 48 hrs, the cells
transfected with GLP-1/Ins/pBud or GLP-1/Neo/pBlu
plasmid were treated with zeocin (Invitrogen, USA) or
geneticin antibiotics (Sigma, USA), respectively. The
media containing antibiotic was replaced every three
days for at least two weeks, until individual clones could
be selected. Five stable clones were isolated for further
studies.
MTT assay was employed to assess the cytotoxicity of
the zeocin and geneticin antibiotics. This assay deter-
mines the appropriate amount of antibiotic sufficient to
kill all cells without the cells developing antibiotic resis-
tant properties. Initially, STC-1 cells (without any anti-
biotic resistant) were treated with different
concentrations of either zeocin or geneticin in the range
of 0 to 1 mg/ml for two weeks. Subsequently, cells were
incubated with MTT (3-(4, 5-dimethylthiozol-2-yl)-3, 5-
dipheryl tetrazolium bromide) (Sigma, USA) for 5 hrs in
37°C followed by the addition of DMSO (Dimethyl sulf-
oxide; Sigma, USA) for 30 min. Finally, optical density
of the solutions was read at 560 nm using an ELISA
plate reader.
Secretion test
Three million of each of the five isolated clones were
grown for two days prior to the experiment. The secre-
tion test was performed as previously described [6,14].
Briefly, the cells were incubated in basal media (5 mM
glucose, 1% FBS) overnight. On the day of the experi-
ment, the media was changed to fresh basal media.
After two hrs, the cells were divided into two groups;
one group was exposed to media containing 5 mM glu-
cose and the second group received media supplemen-
ted with 25 mM glucose for one hour. Finally, the
media and the cells were collected separately for insulin
expression studies.
RT-PCR and quantitative-PCR
Total RNA was extracted from the five isolated clones
and the STC-1 cells using Qiagen RNA extraction kit
(QIAGEN, Germany). The cDNA was synthesised by an
iScript cDNA Synthesis Kit (Bio-Rad, CA); PCR was
then conducted using the specific primers for the target
genes (Table 2). Mouse b-actin was amplified as a posi-
tive control. Q-PCR was performed on the synthesized
cDNA of STC-1 and five isolated clones using an Eva-
Green PCR Kit (Bio-Rad, CA) and a thermal cycler from
Bio-Rad, CA. The data were analysed by CFX Manager
Software (version 1.0.1035.131, Bio-Rad, CA). The
mouse b-actin and b-2 microglobulin values were
employed for normalisation of the Q-PCR data.
ELISA
The insulin secreted into the culture media was deter-
mined using the ultrasensitive human insulin ELISA kit
(ALPCO, USA). This ELISA kit has 100% cross reactiv-
ity with mature human insulin only. The samples for
the ELISA experiment were collected from the media
during the secretion test in different glucose concentra-
tions and at different time points.
Table 1 The primers sequences for PCR amplification and
related restriction enzymes involved
Name Sequences
LP.Bud-F 5’ AT GAG AAA GCT TGT AGA CAG GTG GAG 3’
Hind III
LP.Bud-R 5’ AC AAC ACT AGT GCT TCC AGT CAA ACC 3’
Spe I
Ins-F 5’ AA GTT GTC GAC AGG CTG CAT CAG AAG 3’
Sal I
Ins-R 5’ AT A G GAT CCA CAG GGA CTC CAT CAG 3’
Bam H I
LP.Blu-F 5’ G AAT TCG AGC TGA GAG GAG GTG TAG 3’
EcoRI
LP.Blu-R 5’ C TCG AGA TAC CTG CCT ACC ACT GTC 3’
XhoI
No-F 5’ GA ATT CCA GAA GTA GTG AGG AGG 3’
EcoR I
No-R 5’ T CTA GAT ACA TTG ATG AGT TTG GAC 3’
Xba I
LP.Bud-F and LP.Bud-R are the primers used for amplification of GLP-1
promoter. Hind III and Spe I are the restriction enzymes used to facilitate GLP-
1 promoter cloning into the pBudCE4.1 vector. LP.Blu-F and LP.Blu-R are the
primers for amplification of GLP-1 promoter. EcoR I and Xho I are the
restriction enzymes used to facilitate GLP-1 promoter cloning into the
pBluescript II SK vector. Ins-F and Ins-R are the primers for amplification of
insulin gene. Sal I and BamH I are restriction enzymes used to facilitate the
cloning of insulin gene into the pBudCE4.1 vector. No-F and No-R are the
primers for amplification of neomycin resistant gene. EcoR I and Xba I are the
restriction enzymes used to facilitate the cloning of neomycin resistance gene
into the pBluescript II SK vector. Underlined sequences are the restriction
enzyme sites.
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A native polyacrylamide gel electrophoresis (native-
PAGE) was prepared as previously described [15]. The
total proteins from the cells were separated on the gel
and then transferred onto a nitrocellulose membrane
(Whatman, UK) using a semi-dry system. The presence
of human insulin was detected by incubation of the
membrane with a 1:1000 dilution of the primary anti-
body, a mouse monoclonal antibody against human
insulin (Abcam, UK), followed by incubation in a
1:10,000 dilution of the secondary antibody, a rabbit
polyclonal antibody against mouse IgG conjugated to
alkaline phosphatase (Abcam, UK). Finally, proteins
were visualised using a BCIP-NBT kit (Nacalai Tesque,
Japan). The 5-bromo-4-chloro-3’-indolyphosphate
(BCIP) and the nitro-blue tetrazolium (NBT) react with
alkaline phosphatase to produce a purple compound
which indicates the presence of protein.
Immunocytochemistry
Transfected cells were seeded on a cover-slip two days
prior to the experiment. After the fixation and permeabili-
sation stages, the cells were incubated with the mouse
monoclonal antibody against human insulin (1:200). The
cells were then exposed to goat polyclonal antibody against
mouse IgG conjugated to FITC (Abcam, UK; 1:1000).
Finally, a 1 μg/ml DAPI solution (4,6-diamidino-2-pheny-
lindole; Sigma, USA) was used to dye the nuclei and then
stained cells were imaged by a fluorescence microscope.
Results
Isolation of L-cells
As a basic model for L-cells, GLP-1 -secreting cell line
was generated using the GLP-1/Neo/pBlu plasmid,
which was manipulated in such a manner that the GLP-
1 promoter was located upstream of the neomycin resis-
tant gene (Figure 1-B). It was reported previously that
~5% of STC-1 cells produce GLP-1, whereas no immu-
noreactivity was detected with insulin antibodies [12].
Because the STC-1 cell line is a suitable source of
intestinal cells, it was used for isolation of the L-cells.
The STC-1 cells were transfected with GLP-1/Neo/pBlu
and then treated with 400 μg/ml of geneticin antibiotic,
which was measured using an MTT assay (Figure 2).
After transfection, the cells that received and recognised
the GLP-1 promoter were able to express the neomycin
resistant protein and survive under the geneticin anti-
biotic treatment. The first five stable clones were iso-
lated and then propagated for further analysis.
GLP-1 secretion assay from stable transfected cells
The GLP-1 gene is expressed specifically in L-cells
therefore the presence of its mRNA authenticates the
identity of the isolated transfected cells. The RT-PCR
products of mouse b-actin (578 bp) and mouse GLP-1
(250 bp) mRNA for the five isolated clones were exam-
ined on an agarose gel. As shown in Figure 3, all the
five clones expressed mouse GLP-1 mRNA, thus con-
firming that all the isolated cells were L-cells. Further-
more, because only ~5% of STC-1 cells produce GLP-1,
it was expected that the isolated L-cells would express
more GLP-1 mRNA than primary cells. Therefore, the
GLP-1 expression level of the five isolated clones as well
as of the STC-1 cells (as control) was studied by Q-PCR
(Figure 4). Although the same number of cultured cells
and conditions were used, there was a significant differ-
ence in the GLP-1 expression level of the isolated clones
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Figure 2 An MTT assay was used to check geneticin and
zeocin cytotoxicity level. The viability of STC-1 cells was studied in
the presence of 0 to 1 mg/ml geneticin (diamond) and zeocin
(square) antibiotics. 400 μg/ml of geneticin and 500 μg/ml of zeocin
were the lethal concentrations that kill all the STC-1 cells. Error bars
indicate standard deviation, p < 0.05.
Table 2 The primers sequences for RT-PCR and
quantitative-PCR assays
Name Sequences
GLP-rt-F 5’ GGC ACA TTC ACC AGC GAC TAC 3’
GLP-rt-R 5’ CA ATG GCG ACT TCT TCT GGG 3’
In-rt-F 5’ A ACG AGG CTT CTT CTA CAC ACC 3’
In-rt-R 5’ TTC CAC AAT GCC ACG CTT CTG 3’
Ac-rt-F 5’ GTG TGA TGG TGG GAA TGG GTC 3’
Ac-rt-R 5’ AG GAA GAG GAT GCG GCA GTG 3’
B2m-rt-F 5’ CTG GTC TTT CTG GTG CTT GTC 3’
B2m-rt-R 5’ AT GTG AGG CGG GTG GAA CTG 3’
GLP-rt-F and GLP-rt-R were used to amplify mouse GLP-1 mRNA. In-rt-F and
In-rt-R were used to amplify human insulin mRNA. Ac-rt-F and Ac-rt-R were
used to amplify mouse b-actin mRNA. B2m-rt-F and B2m-rt-R were used to
amplify mouse b-2 microglobulin (b2 m) mRNA.
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mRNA levels among the five isolated clones were
observed. The GLP-1 mRNA expression in clone 2 (L-2)
was about 5.8-fold that of the control. Therefore, the L-
2 clone with the highest GLP-1 expression level was
used for subsequent studies.
Recombinant insulin transfection of L-cell line
To create an insulin-expressing L-cell line, a pBudCE4.1
vector with a zeocin resistance gene was selected, allow-
ing the use of one marker to select L-cells (geneticin)
and one to select insulin-producing cells (zeocin). The
reason for using this vector was because the isolated L-
cells have already been resistant to the neomycin anti-
biotic (geneticin) when they were transfected by GLP-1/
Neo/pBlu plasmid. Therefore, a different vector with
different selectable marker was needed to isolate insulin
expression cell line from the previously isolated L-cells.
The pBudCE4.1 is a co-expression vector with CMV
and EF-1-a promoters. Because the aim of the project
was to study the ability of the GLP-1 promoter to
express the insulin gene, the EF-1-a promoter was
omitted and the CMV promoter was replaced with
GLP-1 promoter. Finally, the human insulin gene was
sub-cloned downstream of the GLP-1 promoter in the
engineered pBudCE4.1 vector (Figure 1-A). The L-2 cell
line was transfected by the GLP-1/Ins/pBud plasmid and
then grown in media containing 500 μg/ml of zeocin
antibiotic; this concentration was determined to be
appropriate by using an MTT assay (Figure 2). The first
five clones that appeared were selected and grown for
further insulin expression analyses.
Secretion of insulin from L-cell line
The expression of insulin mRNA was studied by RT-
PCR using special primers for human insulin mRNA
(150 bp) and using mouse b-actin mRNA (578 bp) as a
positive control. The resulting PCR products indicated
that all five selected cells successfully expressed human
insulin mRNA (Figure 5). The mature and active insulin
protein has a molecular mass of approximately 5.800
kDa and includes two polypeptide chains (A- and B-
chain) that are linked by a disulfide bond [16]. A speci-
fic antibody that reacts only with the intact insulin
molecule (not A-chain, B-chain or pro-insulin) was used
to detect the accurate assembly of the human insulin
protein. The routine PAGE method utilises a reducing
buffer such as SDS and DTT [17]. Because reducing
conditions dissociate the A- and B-chain of the insulin
protein, native-PAGE was employed for insulin analysis.
Furthermore, the SDS-PAGE method is preferable for
the optimal separation of proteins > 30 kDa [17]; there-
fore, for the small insulin protein, native-PAGE is
strongly recommended [15]. The total proteins extracted
from L-1 and L-2 were analysed by western blotting. As
Figure 4 Analysis of GLP-1 mRNA expressions using
quantitative-PCR. GLP-1 expressions in five isolated L-cells and
STC-1 cells (as a control) were measured. All the isolated cells
expressed more GLP-1 mRNA than the control cells. The BioRad CFX
Manager software was employed to analyse GLP-1 expression data.
The mouse b-actin and b-2 microglobulin (b2 m) mRNA levels were
used to normalize the values. Error bars indicate standard deviation,
p < 0.05.
Figure 5 The results of RT-PCR analysis of expressions of
human insulin and mouse b-actin mRNA. Five stable clones in
the antibiotic condition were analysed for insulin gene expression.
The PCR products of the insulin and b-actin genes were 150 bp and
578 bp, respectively, when compared with a 100-bp DNA-ladder. All
the five clones express human insulin mRNA as well as mouse b-
actin.
Figure 3 The results of RT-PCR analysis of expression of mouse
GLP-1 and mouse b-actin mRNA. The five isolated clones from the
STC-1 cell line (1-5) were subjected to RT-PCR. The PCR products of
GLP-1 and b-actin were 250 bp and 578 bp, respectively, when
compared with a 100-bp DNA ladder. All the five clones express
mouse GLP-1 mRNA as well as mouse b- actin.
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insulin, confirmed by analysis of the size and structure
of the protein secreted. Additionally, an immunocyto-
chemical assay exhibited the existence of human insulin
inside the transfected L-cells (Figure 6-B).
The insulin mRNA level was measured by Q-PCR to
verify the effects of glucose concentration on mRNA
synthesis. Although the human insulin mRNA content in
high-glucose media was greater than in the low-glucose
concentration, statistical analyses showed that this increase
was not significant (data not shown). The amount of insu-
lin secreted in response to two different glucose concen-
trations was quantified by ELISA (Figure 7). Insulin levels
in the five isolated clones were significantly increased
when the cells were treated with high glucose media (n =
4, p < 0.005). In 5 mM glucose the highest insulin level
was 1.3 μIU/ml per well (L-2), whereas the lowest was
0.69 μIU/ml (L-5). Samples L-1 and L-2 had the highest
insulin concentration levels in 25 mM glucose, approxi-
mately 3.13 μIU/ml and 3.18 μIU/ml, respectively. To
study the relationship of insulin expression with time, the
insulin level was measured at six time points over a period
of three hrs. L-1 and L-2, which showed the highest insu-
lin secretion levels, were employed for determination of
the speed of insulin secretion in L-cells. Figure 8 shows a
rapid increase of insulin in the first 30 min after the addi-
tion of the media containing 25 mM glucose. After that,
there was a slow but steady rise in the insulin secretion
before reaching a plateau at 90 min.
Discussion
Although there are some enteroendocrine cell lines
available [18], the necessity for pure cells to study GLP-
1 secretion motivated the extraction of L-cells from an
intestinal cell line. Several research groups have
employed an STC-1 cell line to create insulin expression
cells as surrogate b-cells [14,19]. In 2000, Cheung et al.
successfully expressed an insulin gene in STC-1 cells
using a GIP promoter. Their results initiated efforts to
engineer endocrine cells for diabetes treatment [6].
Furthermore, Ramshur et al. (2002) produced insulin/
GIP co-producing cells that secreted insulin and a GIP
protein in response to GIP secretagogues. In this work,
L-cells were successfully isolated from the STC-1 cell
line using the same approach as Ramshur et al. used [7].
We designed a GLP-1/Neo/pBlu plasmid that was spe-
cifically recognised by L-cells, providing an opportunity
Figure 6 The expression of human insulin protein was
analysed using western blotting and immunocytochemistry
assays. (A) The result of western blotting shows that mature human
insulin was secreted by engineered L-cells. Total protein was
extracted from L-1 and L-2. (B) Immunocytochemistry assay
confirmed insulin expression in the L-cells. The green sections show
that the cytoplasm of the cells expresses human insulin, and the
blue sections are nuclei stained by DAPI.
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Figure 7 Glucose responsive insulin secretion was analysed in
L-cells. Insulin expressions in five isolated cells were studied by
ELISA. The samples were collected during secretion tests. Insulin
expression in all the isolated clones increased significantly with 25
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Figure 8 The relationship between the insulin secretion and
time was investigated by ELISA. Clone number 1 and 2 were
used for this experiment. The samples was collected every 30 min
after inducing with glucose. The values were normalized to the
amount of insulin secreted under basal conditions.
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fected cells. The L-cells showed high levels of the GLP-
1 mRNA in comparison with primary STC-1 cells, sug-
gesting that these isolated cells are suitable model for
enteroendocrine L-cells related studies. The Q-PCR
results showed that the levels of GLP-1 mRNA among
the five isolated clones were slightly different. This may
be due to the ability of different cells to express related
genes or the comparative purity of the isolated cells.
T h ec e l l se x t r a c t e db yt h i sm e t h o da r en o to n l yu s e f u l
for studies of insulin expression specifically for diabetes
gene therapy, but they also have potential to become a
model for L-cell line physiology and activity studies in
vitro.
To study insulin expression in the L-cells, we con-
structed a new plasmid that includes a human insulin
gene under the control of the GLP-1 promoter. This
construct could be especially useful for the production
of insulin in L-cells because the pro-glucagon promoter
is cell-specific. Some research groups have studied insu-
lin expression in the L-cell line using a viral promoter
and showed that L-cells were able to produce and
release insulin protein [9,20]. Our results herein also
demonstrate that L-cells can reliably process insulin
production, where successfully expression of insulin was
shown in the isolated L-cells by western blotting and
immunocytochemistry test. However, in our project the
pro-glucagon promoter was utilised to control insulin
gene expression. This unique feature is distinctive and
differentiates our work from the previous ones. In this
study, the insulin producing L-cell line was created by
transfecting isolated L-cells with the manipulated con-
struct (GLP-1/Ins/pBud) and then selecting the cells
with zeocin antibiotic.
Previous studies have revealed that L-cells are glucose
sensitive and respond to glucose changes efficiently.
Reimann et al. (2002) showed that 25 mmol/l of glucose
enhanced GLP-1 secretion up to 3.4-fold compared to
0.5 mmol/l [21]. In addition, Gribble et al. (2003)
showed that a 5 mM glucose concentration increased
GLP-1 secretion and further studied the glucose sensi-
tivity mechanism in L-cells [22]. Our quantitative gene
expression analysis revealed that a 25 mM glucose con-
centration increased insulin secretion up to 2.7-fold (L-
3). Although, the amount of insulin secretion was not
identical in the five isolated clones, they effectively
responded to the change in glucose concentration. On
the other hand, in our study the highest insulin secre-
tion was 3.189 μIU/ml from L-2 in the presence of 25
mM glucose, which was lower than the previous reports
[9,20]. The different expression levels may be due to the
use of different promoters. In the previous reports, the
viral promoter was employed to study the expression of
insulin in L-cells instead. Viral promoters can transcript
a high copy number of their downstream gene and
express genes in all types of cells. These viral features
increase the amount of gene expression that is con-
trolled by the viral promoters.
Q-PCR analysis showed that the transcription expres-
sion level of the insulin gene was not a function of glu-
cose concentration, as no increase in mRNA synthesis
was observed in response to increased level of glucose
in the media. This view is supported with the previous
studies on the expression of insulin using the GIP pro-
moter, where the mRNA expression level of insulin was
not glucose-regulated [7,14]. For a gene therapy
approach, a quick response to nutrient changes is one of
the crucial requirements of an insulin-producing cell
line. Reimann et al. (2004) showed that L-cells have the
ability to respond to stimulators quickly [23]. We also
determined the speed of insulin secretion into the cell
culture media after adding 25 mM glucose. The result
showed that the amount of insulin doubled in the first
30 min but reached a plateau after 90 min. This prop-
erty may be useful for insulin gene therapy because L-
cells are able to respond to fluctuating glucose concen-
trations in a short amount of time.
Conclusions
In conclusion, we established a murine L-cell line that
expressed human insulin under the control of the GLP-
1 promoter. Our data showed that insulin expression
and secretion increased in response to the change in
glucose concentration and also that L-cells efficiently
produced mature insulin protein. Our results revealed
that the GLP-1 promoter and L-cells can be appropriate
candidates for diabetes gene therapy. However, it is very
important that this construct is studied in vivo to verify
its performance in natural situations.
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